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Answer: D {#s1}
=========

The correct answer is fasciculoventricular (FV) pathway and electrophysiological study should be the next step of management. [Figure 1](#F1){ref-type="fig"} demonstrates a 12-lead ECG showing sinus rhythm with a slightly short PR interval of 112 ms and evidence of pre-excitation, especially in precordial leads. The right lateral pathway would have a negative delta wave in lead V1 and left lateral pathway would have it in lead I and aVL. [Figure 2](#F2){ref-type="fig"} demonstrates a junctional rhythm on the first three beats and sinus rhythm on the last three beats of tracing. There is pre-excitation present as seen by slurring in upstroke of leads V2, V3, V4, and limb leads. Of note, the degree of pre-excitation is same in the sinus and junctional beats. In a typical atrioventricular accessory pathway, junctional beats will not show any pre-excitation since the depolarisation starts below the atrium and does not engage the accessory pathway. Hence, the finding of the similar degree of pre-excitation for junctional and sinus beat is diagnostic for FV pathway. Her electrophysiological study confirmed this diagnosis with a fixed HV interval. In addition, she had easily inducible atrioventricular nodal re-entry tachycardia which most likely caused her palpitation. Successful ablation of the slow pathway was performed. A single chamber defibrillator was implanted for prevention of sudden cardiac death from HCM. FV pathway had never been demonstrated to be the key component of re-entrant tachycardia due to its short distance and considered to be benign.[@R1] Its pre-excitation pattern could mimic anteroseptal or mid-septal pathway and lead to the unnecessary risk of complete heart block with an attempted catheter ablation. Danon disease is an X linked dominant lysosomal storage disease derived from the genetic defects in LAMP gene mutation with multiorgan involvement.[@R2] Pre-excitation is very common and risk for sudden cardiac death is high[@R3] in patients with Danon disease.
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